Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01911429 · ClinicalTrials.gov registry record · Phase 3
Pediatric Schizophrenia Efficacy and Safety Study
A Phase 3 study of Schizophrenia, sponsored by Sumitomo Pharma America.
- Completed
- Registry status
- Phase 3
- Development phase
- 327
- Enrollment target
- 20
- Study locations
NCT01911429 is a Phase 3 study of Schizophrenia that has completed, run by Sumitomo Pharma America. The registered enrollment target is 327 participants, above the 218-participant average among 315 other Schizophrenia trials with a reported enrollment target (50% higher). The trial reports 20 study locations across 8 states.
The verdict
NCT01911429, a Phase 3 study of Schizophrenia, has completed, sponsored by Sumitomo Pharma America.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 327 participants
- Enrollment target
- 20
- Study locations
Study Summary
Efficacy and Safety study of Lurasidone in pediatric patients.
Conditions Studied
Interventions
- DRUG Lurasidone 40 mg
- DRUG Lurasidone 80 mg
- DRUG Placebo 40 or 80 mg
Study Locations (20)
California
- California Pharmaceutical Research Institute, Inc - Anaheim
- Central Valley Medical Research - Bakersfield
- ProScience Research Group - Culver City
- Diligent Clinical Trials, Inc - Downey
- Collaborative Neuroscience Network, LLC - Garden Grove
- Global Clinical Trials, LLC - Irvine
- Neuropsychiatric Research Center of Orange County - Orange
- Asclepes Research - Panorama City
- CITrials, Inc. - Riverside & San Bernardino County - Riverside
Florida
- Florida Clinical Research Center, LLC - Bradenton
- Sarkis Clinical Trials - Parent - Gainesville
- APG Research, LLC - Orlando
- Medical Research Group of Central Florida - Sanford
Georgia
- Atlanta Center for Medical Research - Atlanta
- Institute for Behavioral Medicine, LLC - Smyrna
Alabama
- Harmonex Neuroscience Research - Dothan
Connecticut
- Hartford Hospital - Hartford
District of Columbia
- Children's National Medical Center - Washington D.C.
Illinois
- Baber Research Group - Naperville
Louisiana
- Lake Charles Clinical Trials, LLC - Lake Charles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 327 participants |
| Start Date | 2013-08 |
| Est. Completion | 2015-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01911429
The ClinicalTrials.gov registry entry for NCT01911429 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 327 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 218-participant average among 315 other Schizophrenia trials with a reported enrollment target (50% higher). The listed sponsor is Sumitomo Pharma America, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Schizophrenia appearing as the primary indexed condition, and to 3 interventions - of which Lurasidone 40 mg is the first listed.
NCT01911429 reports 20 study locations spanning 8 distinct geographic areas - top geographies include California, Florida, Georgia.
Frequently Asked Questions
What is clinical trial NCT01911429 about?
NCT01911429 is a clinical study titled "Pediatric Schizophrenia Efficacy and Safety Study". Efficacy and Safety study of Lurasidone in pediatric patients.
What is the current status of trial NCT01911429?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 327 participants. The study started on 2013-08. Estimated completion is 2015-12.
What conditions does trial NCT01911429 study?
This clinical trial studies the following conditions: Schizophrenia.
What interventions are being tested in trial NCT01911429?
The interventions under investigation include: Lurasidone 40 mg (DRUG), Lurasidone 80 mg (DRUG), Placebo 40 or 80 mg (DRUG).
Who is sponsoring clinical trial NCT01911429?
This trial is sponsored by Sumitomo Pharma America, which has 168 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01911429 being conducted?
This trial has 20 study locations across Alabama, California, Connecticut, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Schizophrenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia
RECRUITING · Phase 3
-
NBI-1117568-SCZ3030: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia
RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN)
RECRUITING · Phase 3
-
Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 Years of Age) With Schizophrenia
RECRUITING · Phase 3
-
Safety and Efficacy of Brilaroxazine (RP5063) in Schizophrenia
RECRUITING · Phase 3
-
A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With Schizophrenia
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.